Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Deferred Revenue: 2015-2020

Historic Current Deferred Revenue for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2020 value amounting to $1.5 million.

  • Syndax Pharmaceuticals' Current Deferred Revenue rose 717.40% to $12.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $12.4 million, marking a year-over-year increase of 717.40%. This contributed to the annual value of $1.5 million for FY2020, which is negligibly% changed negligibly from last year.
  • Syndax Pharmaceuticals' Current Deferred Revenue amounted to $1.5 million in FY2020, which was down 0.00% from $1.5 million recorded in FY2019.
  • In the past 5 years, Syndax Pharmaceuticals' Current Deferred Revenue registered a high of $1.6 million during FY2017, and its lowest value of $1.2 million during FY2016.
  • Moreover, its 3-year median value for Current Deferred Revenue was $1.5 million (2020), whereas its average is $1.5 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Current Deferred Revenue increased by 28.93% in 2017, and later declined by 3.56% in 2018.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Current Deferred Revenue stood at $1.2 million in 2016, then grew by 28.93% to $1.6 million in 2017, then dropped by 3.56% to $1.5 million in 2018, then remained steady at $1.5 million in 2019, then remained steady at $1.5 million in 2020.